Cyclo Therapeutics: Jumps after genetic disorder treatment meets trial goal

Cyclo Therapeutics

25/03/2021 13:31

** Shares of drug developer  CYTH.O  jump 19.6% to $31.11
premarket
    ** Co says its lead candidate, Trappsol Cyclo, to treat
Niemann-Pick Disease Type C met main efficacy goal of an early
stage study [https://refini.tv/2QDG9e5
]
    ** Some 89% patients showed improvement in disease-related
symptoms that included the ability to walk, speak, swallow,
behavioral features, incontinence, fine motor skills, saccadic
eye movements, and cognition
    ** All 12 patients enrolled in the study received Trappsol
Cyclo intravenously
    ** Condition of 78% patients was rated as improved by
clinicians at end of trial, while remaining were rated stable -
co
    ** Niemann-Pick disease type C is a rare progressive genetic
disorder characterized by an inability of the body to transport
cholesterol and other fatty substances inside of cells
    ** CYTH had more than doubled this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))